Methotrexate, Serum

Understand what Methotrexate, Serum signals

Alternate lab names: MTX
Primary unit: umol/L
LOINC codes: 14836-1
Commercial laboratory assays: 2

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Methotrexate, Serum

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Methotrexate

Laboratory: Quest Diagnostics
Test code: 648
Specimen: Serum
Fasting: Not stated
LOINC: 14836-1
Turnaround: Set up: Mon-Sat

Laboratory assay overview

Methotrexate is an antimetabolite used in the treatment of certain neoplastic diseases, psoriasis and rheumatoid arthritis. In combination with other chemotherapeutic agents, high dose methotrexate doses followed by leucovorin rescue may be effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma. Methotrexate levels are monitored to assess toxicity.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

Population	Range
<5.00 umol/L at 24 hours	<5.00 umol/L at 24 hours
<0.50 umol/L at 48 hours	<0.50 umol/L at 48 hours
<0.20 umol/L at 72 hours	<0.20 umol/L at 72 hours

View complete laboratory reference notes

<5.00 umol/L at 24 hours <0.50 umol/L at 48 hours <0.20 umol/L at 72 hours For conventional low dose leucovorin rescue.

Quest Diagnostics test directory, test code 648

Methotrexate (MTX), Serum or Plasma

Laboratory: Labcorp
Test code: 007658
Specimen: Serum
Fasting: Not stated
LOINC: 14836-1
Turnaround: 2 - 4 days

Laboratory assay overview

Methotrexate, either alone or in combination regimens depending on the patient's risk factors, have been very effective in women with choriocarcinoma and related trophoblastic tumors. Cures have been reported in most individuals treated with low doses of methotrexate plus leucovorin. Although methotrexate induces complete remissions in acute lymphocytic leukemia of childhood, it is of more value for maintenance therapy and is an agent of choice in combination with mercaptopurine. Furthermore, intrathecal methotrexate and cranial irradiation are administered routinely to patients with acute lymphocytic leukemia to prevent meningeal metastases. Methotrexate is a component of combination regimens used to treat non-Hodgkin and Burkitt lymphomas and breast, lung, bladder, cervical, gastric, and ovarian carcinomas. High-dose methotrexate plus leucovorin rescue (with or without other drugs) is used to treat osteogenic sarcoma, some non-Hodgkin lymphomas, and (by some physicians) head and neck tumors. Methotrexate is a primary agent in the treatment of cutaneous T-cell lymphomas and medulloblastoma. It has shown activity as a single agent against testicular cancer; bladder, lung, colorectal, esophageal, hepatocellular, and cervical carcinomas; soft tissue sarcomas; and embryonal rhabdomyosarcoma. For some of these neoplasms (testicular, colorectal, and hepatocellular cancers; soft tissue sarcomas and rhabdomyosarcoma) more effective regimens are available and are used much more frequently than methotrexate.

View complete laboratory reference notes

Therapeutic: 0.02−5.00 μmol/L

Labcorp test directory, test code 007658

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.